Reuters Health: Diuretic effect may not mediate most empagliflozin benefits in heart-failure patients

Diuresis does not appear to play a big role in mediating the benefits of empagliflozin in heart-failure patients, according to results from a large clinical trial.

In the study, researchers examined data on more than 3,700 patients, who all had heart failure and a reduced ejection fraction, randomized to receive either empagliflozin or placebo. Overall, empagliflozin reduced the composite risk of cardiovascular death or hospitalization for heart failure, decreased total hospitalizations for heart failure and improved health status and functional class.

Reuters Health talked to Dr. Mikhail Kosiborod, co-author of an accompanying study and cardiologist at Saint Luke's Mid America Heart Institute, about what the findings mean for patients with reduced ejection fraction and clinical practice moving forward.

Read the full Reuters Health article in M.D. alert: Diuretic effect may not mediate most empagliflozin benefits in heart-failure patients

Related Content

Feb. 18, 2021

MedwireNews: Direct ‘decongestion’ effect shown for empagliflozin in HF
MedwireNews explains the findings of the randomized EMBRACE-HF trial by Dr. Mikhail Kosiborod and his colleagues.
Feb. 10, 2021

BioNexus KC: Saint Luke’s Cardiologist Determined to Improve Diabetes Care, Outcomes
Sometimes the most dangerous element of disease is not its immediate manifestations, but secondary dangers that follow.
Oct. 10, 2020

TCTMD: EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes
In patients remotely monitored with an implanted device, the differences appeared to emerge early and widen with time.